The Kringle-2 domain of tissue plasminogen activator significantly reduces mortality and brain infarction in middle cerebral artery occlusion rats

International Journal of Molecular Medicine

Volumn 26, Issue 2, 2010, Pages 225-230

  Zhang, Haitao ^a   Bi, Feng ^b,c   Xiao, Chunlan ^a   Liu, Jianxia ^c   Wang, Zhixia ^c   Liu, Jian Ning ^a,b   Zhang, Jing ^a,b  

^a NANJING UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c Landing Bio pharmaceuticals Inc   (China)

Author keywords

Blood brain barrier; Ischemia; Kringle; Middle cerebral artery occlusion; Stroke; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTECTIVE AGENT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG PENETRATION; GENE EXPRESSION; KRINGLE DOMAIN; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TISSUE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CHI SQUARE DISTRIBUTION; DISEASE MODEL; DRUG EFFECTS; GENETICS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; METABOLISM; PROTEIN TERTIARY STRUCTURE; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN INFARCTION; CEREBRUM; CHI-SQUARE DISTRIBUTION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INFARCTION, MIDDLE CEREBRAL ARTERY; KRINGLES; MALE; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PROTECTIVE AGENTS; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77955724291     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000456     Document Type: Article

References (30)

1. Lyden PD, Zivin JA, Clark WA, et al: Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology 39: 703-708, 1989.
2. Tsirka SE, Gualandris A, Amaral DG and Strickland S: Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377: 340-344, 1995.
3. Delzoppo GJ, Zeumer H and Harker LA: Thrombolytic therapy in stroke - possibilities and hazards. Stroke 17: 595-607, 1986.
4. Marler JR, Brott T, Broderick J, et al: Tissue-plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587, 1995.
5. Hu CK, Kohnert U, Wilhelm O, Fischer S and Llinas M: Tissue-type plasminogen activator domain-deletion mutant BM 06.022: Modular stability, inhibitor binding, and activation cleavage. Biochemistry 33: 11760-11766, 1994.
6. Wang X, Lee SR, Arai K, et al: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9: 1313-1317, 2003.
7. Su EJ, Fredriksson L, Geyer M, et al: Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14: 731-737, 2008.
8. Qian Z, Gilbert ME, Colicos MA, Kandel ER and Kuhl D: Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361: 453-457, 1993. (Pubitemid 23050134)
9. Indyk JA, Chen ZL, Tsirka SE and Strickland S: Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator/plasmin protease cascade during excitotoxic injury. Neuroscience 116: 359-371, 2003.
10. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG and Lipton SA: Tissue plasminogen activator (TPA) increases neuronal damage after focal cerebral ischemia in wild-type and TPA-deficient mice. Nat Med 4: 228-231, 1998.
11. Nicole O, Docagne F, Ali C, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7: 59-64, 2001.
12. Siao CJ and Tsirka SE: Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 22: 3352-3358, 2002.
13. Kilic E, Hermann DM and Hossmann KA: Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport 10: 107-111, 1999. (Pubitemid 29090488)
14. Yi JS, Kim YH and Koh JY: Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (TPA) or its non-protease mutant S478A-TPA. Exp Neurol 189: 354-360, 2004.
15. Kim YH, Park JH, Hong SH and Koh JY: Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 284: 647-650, 1999.
16. Siddiq MM and Tsirka SE: Modulation of zinc toxicity by tissue plasminogen activator. Mol Cell Neurosci 25: 162-171, 2004. (Pubitemid 38220872)
17. Lee HY, Hwang IY, Im H, Koh JY and Kim YH: Non-proteolytic neurotrophic effects of tissue plasminogen activator on cultured mouse cerebrocortical neurons. J Neurochem 101: 1236-1247, 2007.
18. Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O and Vivien D: Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 27: 155-160, 2004. (Pubitemid 38251516)
19. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK and Lawrence DA: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112: 1533-1540, 2003.
20. Fredriksson L, Li H, Fieber C, Li X and Eriksson U: Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23: 3793-3802, 2004. (Pubitemid 39389710)
21. Nassar T, Akkawi S, Shina A, et al: In vitro and in vivo effects of TPA and PAI-1 on blood vessel tone. Blood 103: 897-902, 2004.
22. Armstead WM, Cines DB and Higazi AAR: Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 36: 2265-2269, 2005.
23. Carroll VA, Leonid LN, Roy B and Adrian LH: Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2. Arterioscler Thromb Vasc Biol 25: 736-741, 2005.
24. Lijnen HR, Nelles L, Van Hoef B, De Cock F and Collen D: Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains. J Biol Chem 265: 5677-5683, 1990.
25. Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91, 1989. (Pubitemid 19040218)
26. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL and Bartkowski HM: Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17: 1304-1308, 1986.
27. Yepes M, Sandkvist M, Wong MKK, et al: Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96: 569-576, 2000.
28. Belayev L, Busto R, Zhao W and Ginsberg MD: Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 739: 88-96, 1996. (Pubitemid 26387366)
29. Aoki T, Sumii T, Mori T, Wang X and Lo EH: Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33: 2711-2717, 2002.
30. Ahn MY, Zhang ZG, Tsang W and Chopp M: Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. Brain Res 837: 169-176, 1999. (Pubitemid 29369228)